It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The interplay between glioma stem cells (GSCs) and the tumor microenvironment plays crucial roles in promoting malignant growth of glioblastoma (GBM), the most lethal brain tumor. However, the molecular mechanisms underlying this crosstalk are incompletely understood. Here, we show that GSCs secrete the Wnt‐induced signaling protein 1 (WISP1) to facilitate a pro-tumor microenvironment by promoting the survival of both GSCs and tumor-associated macrophages (TAMs). WISP1 is preferentially expressed and secreted by GSCs. Silencing WISP1 markedly disrupts GSC maintenance, reduces tumor-supportive TAMs (M2), and potently inhibits GBM growth. WISP1 signals through Integrin α6β1-Akt to maintain GSCs by an autocrine mechanism and M2 TAMs through a paracrine manner. Importantly, inhibition of Wnt/β-catenin-WISP1 signaling by carnosic acid (CA) suppresses GBM tumor growth. Collectively, these data demonstrate that WISP1 plays critical roles in maintaining GSCs and tumor-supportive TAMs in GBM, indicating that targeting Wnt/β-catenin-WISP1 signaling may effectively improve GBM treatment and the patient survival.
The tumour microenvironment plays an important role in promoting glioblastoma. Here, the authors show that glioma stem cells secrete WISP1, which promotes both the survival of the stem cells and tumour-associated macrophages.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
2 University of California, San Diego, Division of Regenerative Medicine, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
3 University Hospitals, Case Western Reserve University, Brain Tumor and Neuro-Oncology Center, Seidman Cancer Center, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847)
4 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Center for Cancer Stem Cell Research, Lerner Research Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
5 Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Lerner Research Institute, Cleveland Clinic, Department of Inflammation and Immunity, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
6 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847)
7 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Center for Cancer Stem Cell Research, Lerner Research Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)